Uterine Cancer Drugs Market is Expected to Gain Popularity Across the Globe by 2028

Uterine cancer is one of the most common gynecologic malignancy among female cancer patients. This uterine cancer is of two types: endometrial cancer and uterine sarcoma. Endometrial cancer is caused due to uncontrolled growth of inner linings of uterus. Endometrial cancer is often curable, however, uterine sarcoma is rare cancer, which develops in the muscle and supporting tissues of the uterus (womb). According to National Cancer Institute, Megestrol Acetate is only drug approved by U.S. Food and Drug Administration (FDA) for the treatment of endometrial cancer till March 2016. Diagnosis of both types of uterine cancer is done through endometrial biopsy, colposcopy or Pap smear screening test.

Uterine Cancer Drugs Market Drivers

Increasing funding for cancer research, rising insurance coverage, and increasing number of new targeted cancer drugs are supporting the revenue growth of uterine cancer drugs market size. For instance, National Cancer Institute, in 2015, invested around US$ 4,480 million on cancer research, which include uterine cancer, cervical cancer, lung cancer, colorectal cancer, liver cancer, breast cancer, leukemia, and ovarian cancer. Furthermore, according to the American Cancer Society, U.S. has spent around US$ 87.8 billion in 2014, on cancer research, in which the major cost accounting for around 44%, was paid by private insurance companies.

Uterine Cancer Drugs Market - Regional Analysis

Geographically, uterine cancer drugs market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. According to World Health Organization (WHO) 2018 data findings, cervical cancer is the fourth most frequent type of cancer in women, which accounted for an estimated 530,000 new cases in 2012, representing 7.9% of all female cancers. Furthermore, according to WHO: 2018, around 90% the 270,000 deaths from cervical cancer in 2015 are occurred in low- and middle-income countries. Furthermore, the prevalence of endometrial cancer is higher in developed economics such as the in North America and the Europe, owing to changing lifestyles of women in these countries. The prevalence of uterine cancer is more common in women aged 50 years and above.

Comments

Life Sciences BPO Market is Expected to Grow Drastically, Assured By Experts From 2023 To 2028

The growing cost of drug development is augmenting the growth of the global life sciences BPO market. For instance, according to a study by the Tufts Center for the Study of Drug Development published in the Journal of Health Economics in May 2019, the cost of drug development was US$ 2.6 billion, which included average out-of-pocket costs of US$ 1.4 billion and time costs of US$ 1.2 billion. Also, patent expiration is another key factor propelling the growth of the life sciences BPO market. For instance, the patent for YAZ (drospirenone/ethinylestradiol), which provides an oral contraceptive regimen, is set to expire in 2021. Furthermore, the rising prevalence of chronic disease around the globe is further anticipated to accelerate the growth of the market. North America is projected to lead the global life sciences BPO market due to increasing R&D in cell therapies by key players in the region. For instance, in February 2020, Caribou Biosciences, Inc., a CRISPR genome editin

Increasing various research activities is propelling growth of the pediatric vaccines market

Pediatric Vaccine Market: Global Trends Over the course of the forecast period, rising public awareness of vaccinations and immunisation is anticipated to fuel market expansion for paediatric vaccines worldwide. For instance, the United States recognises January as Cervical Health Awareness Month, promoting the value of routine immunisation and screening in the fight against cancer. Global Pediatric Vaccine Market: Drivers Increasing awareness regarding vaccines and immunization among the populace is expected to boost growth of the global pediatric vaccine market over the forecast period. For instance, in the U.S., the month of January is celebrated as Cervical Health Awareness Month, wherein the importance of regular vaccination and screening in the prevention of cancer is forwarded.

Epidermolysis Bullosa Therapeutics Market Is Booming Worldwide 2023-2028

Epidermolysis bullosa is a group of rare inherited skin disorders that causes the skin to become very fragile. Any trauma or friction to the skin can cause painful blisters. The symptoms of epidermolysis bullosa include skin that blisters easily, blisters on hands and soles of the feet, thickened skin that may be scarred or change color over time, and thickening of the skin and nails. There are three types of epidermolysis bullosa which includes: · Epidermolysis bullosa simplex (EBS) – the most common type, which can range from mild, with a low risk of serious complications to severe · Dystrophic epidermolysis bullosa (DEB) – which can range from mild to severe · Junctional epidermolysis bullosa (JEB) – a rare form of epidermolysis bullosa that ranges from moderate to severe The type reflects where on the body the blistering takes place and which layer of skin is affected. Global epidermolysis bullosa market is estimated to be valued at US$ 3,

Healthcare News

Search This Blog